Lineage Cell Therapeutics, Inc.

Stocks

LCTX

US53566P1093

Real-time Estimate Cboe BZX Other stock markets 17:21:53 11/06/2026 BST			5-day change	1st Jan Change
1.275 ^USD	+3.66%		+5.37%	-23.65%

05-13	Lineage Cell Therapeutics, Inc., Q1 2026 Earnings Call, May 12, 2026
05-12	Lineage Cell Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Transcript : Lineage Cell Therapeutics, Inc., Q1 2026 Earnings Call, May 12, 2026

Published on 05/13/2026 at 02:35 am BST - Modified on 06/03/2026 at 07:23 pm BST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Welcome to the Lineage Cell Therapeutics First Quarter 2026 Conference Call. [Operator Instructions] An audio webcast of this call is available on the

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Lineage Cell Therapeutics, Inc.

05-13	Lineage Cell Therapeutics, Inc., Q1 2026 Earnings Call, May 12, 2026
05-12	Lineage Cell Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-04	Lineage Cell Therapeutics, Inc. Announces 3 Year Results Of OpRegen Cell Therapy In Patients With Geographic Atrophy	CI
04-28	Canaccord Genuity Initiates Coverage on Lineage Cell Therapeutics With Buy Rating, $9 PT	MT
04-13	Lineage Cell Therapeutics, Inc. Announces Formation of Scientific Advisory Board and Executive Appointment	CI
04-10	Lineage Cell Therapeutics, Inc. Announces Allogeneic Cell Platform Expands into Islet Therapy for Type 1 Diabetes	CI
03-25	B. Riley Raises Price Target on Lineage Cell Therapeutics to $4 From $3, Keeps Buy Rating	MT
03-24	Lineage Cell Therapeutics, Inc. Launches New Corneal Endothelial Cell Therapy Program	CI
03-05	Lineage Cell Therapeutics, Inc., Q4 2025 Earnings Call, Mar 05, 2026
03-05	Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-02	STAAR Surgical Company Announces Interim Co-CEO Appointments, Effective February 1, 2026	CI
01-15	STAAR Surgical Company Announces Board Changes, Effective January 15, 2026	CI
01-06	Lineage Takes Delivery of Gene-Edited Hypoimmune Cell Line Under Partnership with Factor Bioscience	CI
11-28	Lineage Cell Therapeutics Inc withdrew CIRM grant application filed in June 2025 - SEC filing	RE
11-07	Lineage Cell Therapeutics, Inc., Q3 2025 Earnings Call, Nov 06, 2025